A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics of 162 With a Single Ascending Dose in Healthy Adult Subjects
Latest Information Update: 29 Nov 2023
At a glance
- Drugs Hepatitis B surface antigen targeting antibody-Yangshengtang Co. Ltd (Primary)
- Indications Hepatitis B
- Focus Adverse reactions; First in man
- Sponsors Zhejiang Yangshengtang Biotech Co., Ltd.
Most Recent Events
- 23 Nov 2023 Status changed from recruiting to completed.
- 27 Jul 2023 Planned End Date changed from 4 Jul 2023 to 23 Oct 2023.
- 27 Jul 2023 Planned primary completion date changed from 4 Jul 2023 to 3 Aug 2023.